Day One Biopharmaceuticals, Inc.
DAWN
$6.47
$0.172.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.61% | 52.83% | 53.91% | 39.87% | 26.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.25% | 66.66% | 62.93% | 66.56% | 34.52% |
| Operating Income | 13.70% | -3.01% | -9.07% | -61.94% | -34.52% |
| Income Before Tax | 70.36% | 53.23% | 52.08% | 0.14% | -33.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.94% | 49.45% | 51.70% | -0.79% | -33.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.94% | 49.45% | 51.70% | -0.79% | -33.23% |
| EBIT | 13.70% | -3.01% | -9.07% | -61.94% | -34.52% |
| EBITDA | 14.74% | -2.27% | -8.59% | -61.80% | -34.54% |
| EPS Basic | 73.65% | 56.61% | 55.62% | 15.45% | -9.51% |
| Normalized Basic EPS | 75.98% | 62.08% | 58.51% | 18.73% | -6.98% |
| EPS Diluted | 73.57% | 56.57% | 55.46% | 15.23% | -9.72% |
| Normalized Diluted EPS | 75.93% | 62.02% | 58.45% | 18.73% | -6.98% |
| Average Basic Shares Outstanding | 16.56% | 16.91% | 17.19% | 19.55% | 21.31% |
| Average Diluted Shares Outstanding | 16.66% | 17.01% | 17.29% | 19.55% | 21.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |